SHR0532

SHR0532 is a novel small molecule mineralocorticoid receptor antagonist (MRA) developed by Jiangsu Hengrui Pharmaceuticals for the treatment of hypertension. As a potassium-sparing diuretic, it acts by competitively inhibiting the binding of aldosterone to the mineralocorticoid receptor in the distal convoluted tubules and collecting ducts of the nephron. This inhibition prevents the reabsorption of sodium and water while reducing the excretion of potassium, thereby lowering blood pressure without the common side effect of hypokalemia associated with other diuretic classes. SHR0532 is currently undergoing Phase I clinical evaluation to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and patients with mild hypertension.